Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in DFSP and GCF
NCT00085475Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2004
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of imatinib in dermatofibrosarcoma protuberans (DFSP) and giant cell fibroblastoma (GCF), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Progression-free rate at 14 weeks and Therapeutic activity of imatinib mesylate. Started Apr 2004; status: completed.
02
Drugs
03
Conditions
dermatofibrosarcoma protuberans (DFSP)giant cell fibroblastoma (GCF)
Beyond the preview
Go deeper on NCT00085475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085475.